Scholarly article on P(C6H5)3CH3{(1.2-C2B9H11)2Ni*Br} 12570-01-3 from Journal of the American Chemical Society p. 1157 - 1173

DOI: 10.1021/ja00708a009

Source and publish data:

Journal of the American Chemical Society p. 1157 - 1173 (1970)

Update date:2022-08-05

Topics:

Authors:

Warren, L. F.

Hawthorne, M. F.

Read Full Text PDF DownLoad Join now for total 90,000,000 free articles

Article abstract of DOI:10.1021/ja00708a009

Full text of DOI:10.1021/ja00708a009

Products guided by the article

Product name:P(C₆H₅)3CH₃{(1.2-C₂B₉H₁₁)2Ni*Br}

Cas No:12570-01-3

R&D Labs maybe for 12570-01-3

Taimai Sanluck Pharmaceutical Co.,Ltd

Contact:86-592-7662921

Address:8D,No.186,Huarong Road,Huli,Xiamen,China
Allicon Pharmaceuticals,Inc.

Contact:+86-519-86339586，13584329896

Address:Changzhou Scientific and Education Park
JADECHEM NINGBO CO.,LTD.

Contact:+86-574-89075960

Address:#100 Xiang Yun Road, New High tech area, Ningbo, China
Hebei Tianxiang Biological & Pharmaceutical Co., Ltd

Contact:86-0312-6615158

Address:No 42 fazhan street qingyuan county
Zha Yan

Contact:+86-13914766747

Address:Floors 21&22, Jin Cheng Tower, No. 216 Middle Longpan Road, Nanjing

Relevant to this article

Direct access to highly substituted 1-naphthols through palladium-catalyzed oxidative annulation of benzoylacetates and internal Alkynes

Doi:10.1002/chem.201302740
(2013)
Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors

Doi:10.1021/jm049605m
(2004)
Scaling out by microwave-assisted, continuous flow organic synthesis (MACOS): Multi-gram synthesis of bromo- and fluoro-benzofused Sultams Benzthiaoxazepine-1,1-dioxides

Doi:10.1002/chem.201001651
(2010)
Bipyridine- and phenanthroline-based metal-organic frameworks for highly efficient and tandem catalytic organic transformations via directed C-H activation

Doi:10.1021/ja512478y
(2015)
Synthesis and evaluation of bivalent, peptidomimetic antagonists of the α_vβ₃ integrins

Doi:10.1016/j.bmcl.2010.09.035
(2010)
Structural basis for the improved potency of Peroxisome Proliferator-Activated Receptor (PPAR) agonists

Doi:10.1002/cmdc.201000194
(2010)

Article Doi

DOI: 10.1021/ja00708a009